Loading organizations...
Founded in 2013 by Dr. Bradley Messmer and Dr. Thomas Kipps as a UC San Diego spin-out, San Diego-based Abreos Biosciences develops point-of-care diagnostic tests and lateral flow assays measuring active biologic drug levels in patient blood for precision dosing. Operating with under 50 employees, the startup generates revenue through proprietary diagnostic test kits, contract research, and biopharmaceutical partnerships, supplemented by venture investment from TLP Investment Partners LLC and over $1 million in SBIR grants. The company targets clinical laboratories, medical providers, and pharmaceutical companies working with biologic therapies to ensure accurate dosing and verify drug authenticity. Abreos Biosciences holds exclusive licenses to issued patents for its monitoring devices and formed strategic partnerships with entities like Keelung Biologics to develop rapid tests. In 2019, the enterprise launched its first commercial portfolio of research-use-only assay kits for monitoring monoclonal antibodies.
Abreos Biosciences has raised $1.2M across 1 funding round.
Abreos Biosciences has raised $1.2M in total across 1 funding round.
Abreos Biosciences has raised $1.2M in total across 1 funding round.
Abreos Biosciences's investors include TLP Investment Partners.
Abreos Biosciences has raised $1.2M across 1 funding round. Most recently, it raised $1.2M Other Equity in June 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 6, 2017 | $1.2M Venture Round | TLP Investment Partners | — | Announced |
